key: cord-1016691-usopx3mj
authors: Kumar Shukla, Dr Ajay; Misra, Dr Saurav
title: Antiviral Effects of Ivermectin in COVID-19- Clinically Plausible
date: 2021-06-24
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.06.048
sha: c6150338318d20deafd2685559ba224e3a132357
doc_id: 1016691
cord_uid: usopx3mj

nan

These results could due to the dose of ivermectin used in the study which is lower than that needed for achieving optimal plasma concentration for antiviral activity. Previous evidence from preclinical and observational studies supports our premise.

In a study demonstrating the in vitro antiviral activity of ivermectin, upon incubation of 

A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients

Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety

Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects

Effect of Ivermectin on Time to Resolution of Symptoms Among Adults with Mild COVID-19: A Randomized Clinical Trial

 WHO advises that ivermectin only be used to treat COVID-19 within clinical trials

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.